The FDA's Natural Desiccated Thyroid Ban: 2026 Update
Key Takeaways
- The FDA's August 2025 letters told manufacturers of natural desiccated thyroid (NDT) to stop marketing within roughly 12 months and told patients to transition to approved drugs.
- On March 11, 2026, the FDA replaced that letter. The hard deadline and the transition language are gone.
- Armour Thyroid, NP Thyroid, and other NDT products remain legal to manufacture, prescribe, and fill.
- The FDA now says it supports the first formal approval of a desiccated thyroid extract product and will publish draft compliance guidance by August 2026.
- A 2026 study of 1.26 million patients linked T3-containing therapy, including NDT, with lower dementia and mortality risk than levothyroxine alone.
- The biggest current obstacle is insurance. CVS Caremark dropped NDT from its standard formulary in April 2026.
This article is for educational purposes only and is not medical advice. Do not stop or change thyroid medication without working with your healthcare provider. Thyroid hormone dosing is individual and requires monitoring.
Updated August 2026
This article was first published in August 2025, when the FDA announced it would remove natural desiccated thyroid medications from the market. That plan has since been walked back. On March 11, 2026, the FDA issued a revised letter to manufacturers that removed the removal deadline and the instruction for patients to switch to synthetic thyroid drugs. The full timeline, the current rules, and the new insurance problem are covered below.
In August 2025, the FDA announced enforcement action against animal-derived thyroid medications, also called natural desiccated thyroid (NDT) or desiccated thyroid extract (DTE). These are prescription medications like Armour Thyroid and NP Thyroid, made from porcine thyroid glands, and they have been used to treat hypothyroidism for over 130 years. Roughly 1.5 million Americans rely on them, many after failing to feel well on synthetic levothyroxine.
What followed was a year of public pushback, leadership changes at the agency, new research favoring NDT, and finally a reversal. Here is where everything stands as of August 2026.
What the FDA Announced in August 2025
On August 6, 2025, the FDA sent letters to manufacturers, importers, and distributors of animal-derived thyroid medications stating that these products are unapproved and could not continue to be marketed without going through the approval process. Patients were encouraged to work with their doctors to transition to an FDA-approved medication within about 12 months. In practice, that meant NDT would have disappeared from pharmacy shelves by late summer 2026.
NDT is a small slice of the thyroid medication market. Based on ClinCalc prescription data for 2023, levothyroxine accounted for roughly 80.9 million prescriptions at about $21 each, around $1.71 billion in total drug cost. NDT accounted for roughly 3.95 million prescriptions at about $65 each, around $0.26 billion. The people using NDT are largely people who already tried the synthetic version and did not feel well on it. Removing their option would have pushed nearly all of them back onto products they had already rejected, to the direct benefit of synthetic manufacturers.
Why Did the FDA Target Natural Desiccated Thyroid?
The FDA's stated concerns were "safety, purity and potency" and potential "quality and dosing issues." The argument is that because these medications come from animal glands, hormone content may vary between batches. The announcement did not cite documented cases of patient harm from currently marketed NDT products.
Potency problems are not unique to animal-derived products. In June 2025, Accord Healthcare recalled over 82,000 bottles of levothyroxine after testing found the tablets were subpotent, one of several levothyroxine recalls that year totaling more than 160,000 bottles. Another multi-strength levothyroxine recall for subpotency followed in July 2026. Batch variability is a manufacturing quality problem that applies across the industry, and the FDA already has tools to act against any manufacturer, natural or synthetic, that fails quality standards.
It is also worth remembering the scale of harm the medical system tolerates elsewhere. A 2016 BMJ analysis estimated that medical error would rank as the third leading cause of death in the US if it were tracked as one. That estimate is debated, and its co-author, Dr. Marty Makary, now runs the FDA. Against that backdrop, removing a medication with a 130-year track record and no cited harm cases was a hard action to justify, and the public said so loudly.
Levothyroxine vs Natural Desiccated Thyroid
| Category | Levothyroxine (T4) | Natural Desiccated Thyroid (NDT/DTE) |
|---|---|---|
| What it is | Synthetic T4 only. Standard first-line therapy. Relies on your body converting T4 to active T3. | Porcine thyroid extract containing both T4 and T3, plus trace thyroid compounds. |
| Common side effects | Mostly dose-related. Too high: palpitations, anxiety, insomnia, heat intolerance. Too low: fatigue, weight gain, cold intolerance, low mood. | Similar dose-related effects. Hyperthyroid-like symptoms can appear near the T3 peak shortly after dosing. |
| Serious risks if overdosed | Atrial fibrillation, bone loss with long-term TSH suppression, strain in existing heart disease. | Same risks if TSH is suppressed. Caution advised with cardiovascular disease and osteoporosis. |
| Strengths | Most studied, consistent potency, wide availability, flexible dosing. | Contains T3 directly. Some patients report better symptom relief, especially poor T4-to-T3 converters. |
| Weaknesses | Some patients stay symptomatic despite normal labs. Repeated subpotency recalls. | Shorter T3 half-life can cause peaks and troughs. Smaller evidence base. Possible batch variability. |
Most reported side effects for either option reflect under- or over-replacement rather than a true reaction to the drug itself.
What the Research Shows
If NDT caused the problems the FDA implied, patients would have switched on their own. The synthetic option is cheaper, easier to get, and covered by every insurance plan. People stay on NDT because they feel better on it, and the research gives that experience some support.
The 2013 crossover trial
A randomized, double-blind crossover study of 70 hypothyroid patients at Walter Reed compared NDT with levothyroxine, with each patient trying both for 16 weeks. Objective symptom and cognitive scores showed no difference between the two treatments. When asked which they preferred at the end, 48.6 percent chose NDT versus 18.6 percent who chose levothyroxine, and the NDT preference group lost a modest amount of weight. A blinded preference gap that wide suggests some patients notice a difference that standard labs do not capture.
The 2024 systematic review
A systematic review published in Thyroid examined nine nonrandomized studies, two randomized trials, and three case reports comparing NDT with levothyroxine or combination therapy. The two randomized trials found no difference in quality of life or symptoms, which positions NDT as a comparable option rather than an inferior one. The nonrandomized studies favored NDT on symptoms and quality of life. The authors rated overall study quality as limited and noted possible increases in heart rate and reductions in HDL with NDT, with conflicting results across studies. Evidence tier: moderate for comparability, weaker for superiority.
The 2026 dementia and mortality study
The strongest new data arrived after the FDA's announcement. A study published in the Journal of Clinical Endocrinology and Metabolism analyzed records from 1.26 million hypothyroid patients and 3.32 million controls over a 20-year window. Patients treated with levothyroxine alone carried a higher risk of dementia and more than double the risk of death compared with controls, even when their TSH levels were normal. Patients whose treatment contained T3, either synthetic combination therapy or desiccated thyroid extract, showed reduced dementia and mortality risk. This is observational data, so it shows association rather than proof of cause, but it directly challenges the assumption that a normal TSH on levothyroxine means the job is done. The senior author, Dr. Antonio Bianco, is a former president of the American Thyroid Association.
Banning the main T3-containing option while this evidence was emerging would have been a remarkable decision, and it appears the FDA came to the same conclusion.
Where Things Stand Now
Public response to the August 2025 announcement was intense. Patient petitions gathered thousands of signatures, thyroid advocacy groups mobilized, and independent health media covered the story extensively. FDA Commissioner Marty Makary posted on X that the agency was committed to pursuing the first-ever approval of desiccated thyroid extract and would ensure access in the meantime, a message reposted by HHS Secretary Robert F. Kennedy Jr. The policy shift also followed the departure of George Tidmarsh, an FDA official who had opposed NDT.
On March 11, 2026, the FDA formalized the reversal in a new letter to manufacturers, importers, and distributors. The key changes: the language directing patients to transition to approved medications was removed, the August 2026 removal deadline was replaced with a plan to issue draft guidance on "compliance priorities" by August 2026, and the agency committed to a risk-based enforcement approach, meaning it will act against manufacturers with genuine quality failures rather than against the product category as a whole.
The approval pathway is also moving. Acella Pharmaceuticals and its sister company Neuvosyn Laboratories announced positive topline results in September 2025 from a Phase II randomized, double-blind trial of North Star, an investigational desiccated thyroid product they intend to submit for approval as a biologic. If approved, it would be the first NDT product to hold formal FDA approval, which would settle the "unapproved" objection permanently.
Two cautions. First, enforcement discretion is policy, not law. The current leadership supports access, and a future administration could reverse course again. Second, NDT products remain technically unapproved until a license is granted, which leaves them exposed to exactly the kind of pressure described next.
The New Problem Is Insurance, Not the FDA
While the FDA softened, pharmacy benefit managers moved in the opposite direction. Starting April 1, 2026, CVS Caremark, which manages prescription benefits for a large share of American health plans including some Aetna plans, removed NDT medications from its standard formulary. Patients on affected plans now pay cash or fight for exceptions, even though the medication remains fully legal.
If your coverage dropped NDT, you have options. Your prescriber can file a formulary exception or prior authorization documenting that you failed levothyroxine. AbbVie has offered a coupon program for Armour Thyroid for patients not on government-subsidized plans, and Acella has published access and pricing guidance for NP Thyroid. Cash prices at independent pharmacies and discount programs are often lower than people expect. It is worth pricing all of these before assuming the medication is out of reach.
Final Thoughts
The lesson of the past year is that public pressure works. A medication with a 130-year track record was months away from disappearing, patients and practitioners refused to accept it, and the agency changed course. That should not have been necessary. If a regulator wants to remove a treatment that pharmaceutical competitors stand to profit from, the burden of proof belongs on the regulator, and documented harm should be the standard. A ban would also have pushed patients toward overseas sources with far less verifiable quality, creating the exact safety problem the FDA claimed to be solving.
I have watched my own mild hypothyroidism reverse with dietary changes: removing anti-thyroid nutrients, a daily raw carrot salad, limiting phytoestrogens, supporting liver function, and progesterone supplementation. If you have been diagnosed with hypothyroidism, I recommend looking into Dr. Ray Peat's work on thyroid-friendly eating. This is my personal experience, not medical advice, and medication decisions belong in a conversation with your provider.
Frequently Asked Questions
Is Armour Thyroid being banned in 2026?
No. The FDA's March 11, 2026 letter removed the removal deadline from its August 2025 announcement. Armour Thyroid, NP Thyroid, and other NDT products remain available by prescription while manufacturers pursue formal approval.
Can I still fill my natural desiccated thyroid prescription?
Yes. NDT remains legal to manufacture, prescribe, and dispense. The main obstacle for some patients is insurance coverage rather than availability.
Why did the FDA target natural desiccated thyroid?
NDT products have never gone through formal FDA approval, and the agency cited concerns about safety, purity, and potency tied to their animal origin. The announcement did not cite documented harm from currently marketed products.
Will insurance cover NDT in 2026?
It depends on your plan. CVS Caremark removed NDT from its standard formulary in April 2026. Formulary exceptions, manufacturer coupons, and cash pricing at independent pharmacies are the main workarounds.
Is an FDA-approved natural thyroid medication coming?
Possibly. Neuvosyn Laboratories reported positive Phase II results for North Star, an investigational desiccated thyroid product, in September 2025 and intends to seek approval through the biologics pathway. The FDA has said it supports a first-ever DTE approval.
Sources
- FDA. Letter to Manufacturers, Importers, and Distributors of Animal-Derived Thyroid Products. March 11, 2026. fda.gov/media/191621
- FDA. FDA's Actions to Address Unapproved Thyroid Medications. August 2025, revised March 2026.
- Beltrão FEL, Carvalhal G, Meneghini V, et al. Treatment of Hypothyroidism That Contains Liothyronine is Associated With Reduced Risk of Dementia and Mortality. J Clin Endocrinol Metab. 2026;111(2):561-571. doi.org/10.1210/clinem/dgaf367
- Hoang TD, Olsen CH, Mai VQ, Clyde PW, Shakir MK. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab. 2013;98(5):1982-1990. doi.org/10.1210/jc.2012-4107
- Riis KR, Larsen CB, Bonnema SJ. Potential Risks and Benefits of Desiccated Thyroid Extract for the Treatment of Hypothyroidism: A Systematic Review. Thyroid. 2024;34(6):687-701. doi.org/10.1089/thy.2023.0649
- Acella Pharmaceuticals. Press release: Acella Thanks FDA for Maintaining Access to Desiccated Thyroid Extract Products. March 25, 2026.
- ClinCalc DrugStats Database. Levothyroxine and Thyroid (Desiccated) prescription estimates, 2023.
- Makary MA, Daniel M. Medical error, the third leading cause of death in the US. BMJ. 2016;353:i2139. doi.org/10.1136/bmj.i2139 (methodology contested)
